JP6963146B1 - 癌を治療するためのkras阻害剤の投与 - Google Patents
癌を治療するためのkras阻害剤の投与 Download PDFInfo
- Publication number
- JP6963146B1 JP6963146B1 JP2021500906A JP2021500906A JP6963146B1 JP 6963146 B1 JP6963146 B1 JP 6963146B1 JP 2021500906 A JP2021500906 A JP 2021500906A JP 2021500906 A JP2021500906 A JP 2021500906A JP 6963146 B1 JP6963146 B1 JP 6963146B1
- Authority
- JP
- Japan
- Prior art keywords
- compound
- cancer
- patients
- kras
- tumor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 CCCc(nccc1C)c1N(C(N)=*)c(c(*N(CC1)C(C)CN1C(C=C)=*)c1)nc(-c(c(O)ccc2)c2F)c1F Chemical compound CCCc(nccc1C)c1N(C(N)=*)c(c(*N(CC1)C(C)CN1C(C=C)=*)c1)nc(-c(c(O)ccc2)c2F)c1F 0.000 description 2
- VQKNEMIPXNPWTN-SFHVURJKSA-N CCCc1nccc(C)c1N(c(nc(c(F)c1)-c(c(F)ccc2)c2O)c1C(N(CC1)[C@@H](C)CN1C(C=C)=O)=N1)C1=O Chemical compound CCCc1nccc(C)c1N(c(nc(c(F)c1)-c(c(F)ccc2)c2O)c1C(N(CC1)[C@@H](C)CN1C(C=C)=O)=N1)C1=O VQKNEMIPXNPWTN-SFHVURJKSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Description
本出願は、2019年5月14日出願の米国仮特許出願第62/847,862号及び2019年6月27日に出願の米国仮特許出願第62/867,747号の利益を主張するものであり、前記特許はどちらも本明細書に完全に記載されているかのように全体として及びあらゆる目的のために参照により本明細書に組み込まれる。
第1実施形態では、本開示は、癌を治療する方法であって、それを必要とする対象に180mg、360mg、720mg若しくは960mgの1日量で化合物Aを投与するステップを含み、ここで化合物Aが、以下の構造:
本明細書に開示した方法の実施形態では、対象には化合物Aが本明細書に開示した用量で少なくとも1カ月間、少なくとも6週間、少なくとも2カ月間、少なくとも3カ月間、少なくとも4カ月間、少なくとも5カ月間又は少なくとも6カ月間投与される。
一部の実施形態では、本明細書に開示した方法における化合物Aによって治療される対象は、少なくとも1種以上の先行全身性癌療法を受けていた対象である(例えば、化合物Aは、第2選択又は第3選択療法である)。一部の実施形態では、本明細書に開示した方法における化合物Aによって治療される対象は、少なくとも1種の先行全身性癌の後に疾患の増悪を有する対象である(即ち、化合物Aは、第2選択療法である)。一部の実施形態では、本明細書に開示した方法における化合物Aによって治療される対象は、少なくとも2種の先行全身性癌療法の後に疾患の増悪を有する対象である(即ち、化合物Aは、第3選択療法である)。先行全身性癌療法は、規制当局(例えば、FDA又はEMA)によって所定のタイプ及び病期の癌の治療として承認された任意の療法であり得る。一部の場合に、先行全身性癌療法は、規制当局によっては未だ承認されていないが臨床試験を受けている癌療法である。対象が先行全身性癌療法を受けていた場合は、一部の場合に、対象は、化合物Aを用いる本明細書に開示した療法を開始する前に、少なくとも1カ月間、少なくとも2カ月間、少なくとも3カ月間、少なくとも4カ月間、少なくとも5カ月間又は少なくとも6カ月間に渡り何れかの全身性癌療法を受けていなかった。
血液学的毒性:発熱性好中球減少症;好中球減少性感染症;グレード4の好中球減少症;>7日間のグレード≧3の血小板減少症;≧2のグレードの出血を伴うグレード3の血小板減少症;グレード4の血小板減少症;グレード4の貧血
非血液学的毒性:グレード≧4の嘔吐若しくは下痢;グレード3の下痢若しくは最高の医療支援にもかかわらず4日間以上持続するグレード3の嘔吐;最高の医療支援にもかかわらず3日間以上に渡るグレード≧3の悪心;何れかの他のグレード≧3のAE
本開示は、他の経路若しくは同じ経路の他の成分を調節することが知られている薬剤又は更に標的酵素の重複するセットが化合物A又はその薬学的に許容される塩と組み合わせて使用される、併用療法の方法も又提供する。一態様では、そのような療法は、相乗的又は相加的な治療効果を提供するために、本明細書に開示した化合物Aと化学療法剤との併用を含むが、これには限定されない。
A.最初の結果
化合物Aの投与試験:本試験には、KRAS G12C突然変異を有する癌であると同定された患者が登録された。患者は、局所進行性若しくは転移性KRAS G12C突然変異固形腫瘍を有する成人患者であった。全患者は、以前に腫瘍のタイプ及び疾患病期に依存する先行標準療法を受けていた。進行性脳転移を示した患者はいなかった。投与試験を受ける患者は、次の診断を受けていた:14例は非小細胞肺癌(NSCLC)、10例は結腸直腸癌(CRC)及び2例は別のKRAS G12C突然変異固形腫瘍の診断を受けていた。化合物Aは、指定用量で1日1回経口投与された。患者には180mg、360mg、720mg又は960mgの用量の化合物Aが投与され、6週間毎に放射線による精査が実施された。
この試験の更新された結果は、これによりその内容が全体として本明細書に組み込まれる、スペインのバルセロナで2019年9月27日〜10月1日まで開催された欧州臨床腫瘍学会議(European Society of Medical Onclology(ESMO))の会議でGovindan,R.,et.al.,“Phase 1 Study of AMG 510,a Novel KRASG12C Inhibitor,in Advanced Solid Tumors With KRAS p.G12C Mutation”によってポスターとして提示されている。本試験の詳細な結果は、それらの内容が全体として本明細書に組み込まれる、米国眼治療学会議(ASCO)の2020年5月29〜31日の会議(バーチャル)でFakih,M.G.,et al.,‘‘CodeBreak 100:activity of AMG 510,a novel small molecule inhibitor of KRASG12C,in patients with advanced colorectal cancer’’及びHong,D.S.,et al.,“CodeBreak 100:Phase 1 study of AMG 510,a novel KRASG12C inhibitor,in patients with advanced solid tumors other than non−small−cell lung cancer(NSCLC)and colorectal cancer(CRC)’’によって提示されるであろう。
最初の患者は、2018年8月27日に登録された。2019年7月17日のカットオフ日現在までに患者76例が登録されたが、それらの内患者34例はNSCLCを有していた(SCLCの患者1例(この患者はカットオフ日現在にSCLC(「他の腫瘍タイプ」カテゴリー)であると記録されていたが、カットオフ後に治験参加機関によってNSCLCに変更された)。患者45例は用量漸増コホートに登録され(総1日量180mg(N=6)、総1日量360mg(N=13)、総1日量720mg(N=11)、総1日量960mg(N=15))、患者31例は用量拡大コホートに登録され(総1日量960mg(N=31))、初回の6週間毎の精査を受けた、又は早期進行(PD)を示した55例の患者が評価可能となった。登録患者76例中、52例は治療中のままとなったが、24例はPD(N=22)及び死亡(N=2)のために治療を中止した。ここで注目に値するのは、治療関連有害事象による治療中止が1例も誘発されなかったことである。
2020年1月8日のカットオフ日現在、CRC患者42例が登録された(総1日量180mgのコホート1:患者3例、総1日量360mgのコホート2:患者10例、総1日量720mgのコホート3:患者4例;総1日量960mgのコホート4:患者25例)。メジアンフォローアップ期間は、7.9カ月間(範囲:4.2〜15.9カ月間)であった。患者8例は、治療を継続した。患者34例は、疾患の進行(32例)及び患者(2例)からの要請のために治療を中止した。全登録患者は、先行ラインの全身性抗癌療法を受けていた。患者の45%は、4ライン以上の治療を受けた。
2020年1月8日のカットオフ日までに、下記の腫瘍タイプ:膵臓癌(10例)、虫垂癌(4例)、子宮内膜癌(2例)、原発巣不明癌(2例)、胆管癌(1例)、副鼻腔癌(1例)、乳頭部癌(1例)、小腸癌(1例)、黒色腫(1例)、小細胞肺癌(1例)及び食道癌(1例)の患者25例が登録された。虫垂癌の患者2例は、化合物Aのそれぞれ360及び720mgの総1日量を摂取した。残りの患者23例は、総1日量960mgの化合物Aを摂取した。メジアンフォローアップ期間は、4.3カ月間(範囲:0.1〜12.6カ月間)であった。患者22例は7週間以上のフォローアップ検査を受けており、応答について評価可能であった。カットオフ日までに、患者12例は、最も一般的な原因として進行を示し、治療を中止した。全登録患者は、先行ラインの全身性抗癌療法を受けており、登録患者の84%は、2つ以上の先行ラインを受けていた。
Claims (8)
- 前記患者が、前記化合物を最初に投与する前に、少なくとも1種の全身性がん療法を受けている、請求項1に記載の医薬組成物。
- 前記化合物が経口投与される、請求項1又は2に記載の医薬組成物。
- 前記化合物が錠剤として投与される、請求項1〜3の何れか一項に記載の医薬組成物。
- 前記患者が、前記化合物を最初に投与する前に、少なくとも1種の全身性がん療法を受けている、請求項5に記載の使用。
- 前記化合物が経口投与される、請求項5又は6に記載の使用。
- 前記化合物が錠剤として投与される、請求項5〜7の何れか一項に記載の使用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2021168089A JP7265600B2 (ja) | 2019-05-14 | 2021-10-13 | 癌を治療するためのkras阻害剤の投与 |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962847862P | 2019-05-14 | 2019-05-14 | |
US62/847,862 | 2019-05-14 | ||
US201962867747P | 2019-06-27 | 2019-06-27 | |
US62/867,747 | 2019-06-27 | ||
PCT/US2020/032686 WO2020232130A1 (en) | 2019-05-14 | 2020-05-13 | Dosing of kras inhibitor for treatment of cancers |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021168089A Division JP7265600B2 (ja) | 2019-05-14 | 2021-10-13 | 癌を治療するためのkras阻害剤の投与 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP6963146B1 true JP6963146B1 (ja) | 2021-11-05 |
JP2021534080A JP2021534080A (ja) | 2021-12-09 |
Family
ID=68531369
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021500906A Active JP6963146B1 (ja) | 2019-05-14 | 2020-05-13 | 癌を治療するためのkras阻害剤の投与 |
JP2021168089A Active JP7265600B2 (ja) | 2019-05-14 | 2021-10-13 | 癌を治療するためのkras阻害剤の投与 |
JP2023065418A Active JP7300076B1 (ja) | 2019-05-14 | 2023-04-13 | 癌を治療するためのkras阻害剤の投与 |
JP2023098289A Pending JP2023116708A (ja) | 2019-05-14 | 2023-06-15 | 癌を治療するためのkras阻害剤の投与 |
Family Applications After (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021168089A Active JP7265600B2 (ja) | 2019-05-14 | 2021-10-13 | 癌を治療するためのkras阻害剤の投与 |
JP2023065418A Active JP7300076B1 (ja) | 2019-05-14 | 2023-04-13 | 癌を治療するためのkras阻害剤の投与 |
JP2023098289A Pending JP2023116708A (ja) | 2019-05-14 | 2023-06-15 | 癌を治療するためのkras阻害剤の投与 |
Country Status (13)
Country | Link |
---|---|
US (2) | US11426404B2 (ja) |
EP (2) | EP3738593A1 (ja) |
JP (4) | JP6963146B1 (ja) |
CN (1) | CN113840606B (ja) |
AU (1) | AU2020275845A1 (ja) |
BR (1) | BR112021022812A2 (ja) |
CA (1) | CA3139519A1 (ja) |
IL (1) | IL287838A (ja) |
MA (1) | MA55959A (ja) |
MX (1) | MX2021013788A (ja) |
SG (1) | SG11202112432PA (ja) |
TW (2) | TWI824148B (ja) |
WO (1) | WO2020232130A1 (ja) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RS62456B1 (sr) | 2016-12-22 | 2021-11-30 | Amgen Inc | Derivati benzizotiazola, izotiazolo[3,4-b]piridina, hinazolina, ftalazina, pirido[2,3-d]piridazina i pirido[2,3-d]pirimidina kao kras g12c inhibitori za tretman raka pluća, pankreasa ili debelog creva |
JOP20190272A1 (ar) | 2017-05-22 | 2019-11-21 | Amgen Inc | مثبطات kras g12c وطرق لاستخدامها |
CA3075046A1 (en) | 2017-09-08 | 2019-03-14 | Amgen Inc. | Inhibitors of kras g12c and methods of using the same |
MA52496A (fr) | 2018-05-04 | 2021-03-10 | Amgen Inc | Inhibiteurs de kras g12c et leurs procédés d'utilisation |
MA52501A (fr) | 2018-05-04 | 2021-03-10 | Amgen Inc | Inhibiteurs de kras g12c et leurs procédés d'utilisation |
US11932633B2 (en) | 2018-05-07 | 2024-03-19 | Mirati Therapeutics, Inc. | KRas G12C inhibitors |
WO2019217691A1 (en) | 2018-05-10 | 2019-11-14 | Amgen Inc. | Kras g12c inhibitors for the treatment of cancer |
JP7360396B2 (ja) | 2018-06-01 | 2023-10-12 | アムジエン・インコーポレーテツド | Kras g12c阻害剤及び同一物の使用方法 |
WO2020050890A2 (en) | 2018-06-12 | 2020-03-12 | Amgen Inc. | Kras g12c inhibitors and methods of using the same |
JP7516029B2 (ja) | 2018-11-16 | 2024-07-16 | アムジエン・インコーポレーテツド | Kras g12c阻害剤化合物の重要な中間体の改良合成法 |
WO2020106640A1 (en) | 2018-11-19 | 2020-05-28 | Amgen Inc. | Kras g12c inhibitors and methods of using the same |
JP7377679B2 (ja) | 2018-11-19 | 2023-11-10 | アムジエン・インコーポレーテツド | がん治療のためのkrasg12c阻害剤及び1種以上の薬学的に活性な追加の薬剤を含む併用療法 |
WO2020146613A1 (en) | 2019-01-10 | 2020-07-16 | Mirati Therapeutics, Inc. | Kras g12c inhibitors |
EP3738593A1 (en) * | 2019-05-14 | 2020-11-18 | Amgen, Inc | Dosing of kras inhibitor for treatment of cancers |
MX2021014126A (es) | 2019-05-21 | 2022-01-04 | Amgen Inc | Formas en estado solido. |
EP4021444A4 (en) | 2019-08-29 | 2023-01-04 | Mirati Therapeutics, Inc. | G12D KRAS INHIBITORS |
CA3152025A1 (en) | 2019-09-24 | 2021-04-01 | David BRIERE | Combination therapies |
US20230028414A1 (en) * | 2019-12-16 | 2023-01-26 | Amgen Inc. | Dosing regimen of kras g12c inhibitor |
CN115135315A (zh) | 2019-12-20 | 2022-09-30 | 米拉蒂治疗股份有限公司 | Sos1抑制剂 |
BR112023018734A2 (pt) * | 2021-03-17 | 2023-10-24 | Amgen Inc | Regimes de dosagem de sotorasib |
IL307849A (en) * | 2021-05-06 | 2023-12-01 | Amgen Inc | Sutorsive formulation |
TW202340202A (zh) | 2021-12-22 | 2023-10-16 | 美國加利福尼亞大學董事會 | Gtp酶抑制劑及其用途 |
WO2024082724A1 (en) * | 2022-10-17 | 2024-04-25 | Ningbo Newbay Technology Development Co., Ltd. | Pim kinase inhibitor in combination with kras inhibitor |
Family Cites Families (227)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4232027A (en) | 1979-01-29 | 1980-11-04 | E. R. Squibb & Sons, Inc. | 1,2-Dihydro-2-oxo-4-phenyl-3-quinolinecarbonitrile derivatives |
EP0090505B1 (en) | 1982-03-03 | 1990-08-08 | Genentech, Inc. | Human antithrombin iii, dna sequences therefor, expression vehicles and cloning vectors containing such sequences and cell cultures transformed thereby, a process for expressing human antithrombin iii, and pharmaceutical compositions comprising it |
GB8827305D0 (en) | 1988-11-23 | 1988-12-29 | British Bio Technology | Compounds |
JP2762522B2 (ja) | 1989-03-06 | 1998-06-04 | 藤沢薬品工業株式会社 | 血管新生阻害剤 |
US5112946A (en) | 1989-07-06 | 1992-05-12 | Repligen Corporation | Modified pf4 compositions and methods of use |
PT98990A (pt) | 1990-09-19 | 1992-08-31 | American Home Prod | Processo para a preparacao de esteres de acidos carboxilicos de rapamicina |
US5892112A (en) | 1990-11-21 | 1999-04-06 | Glycomed Incorporated | Process for preparing synthetic matrix metalloprotease inhibitors |
US5120842A (en) | 1991-04-01 | 1992-06-09 | American Home Products Corporation | Silyl ethers of rapamycin |
US5100883A (en) | 1991-04-08 | 1992-03-31 | American Home Products Corporation | Fluorinated esters of rapamycin |
US5118678A (en) | 1991-04-17 | 1992-06-02 | American Home Products Corporation | Carbamates of rapamycin |
AU658646B2 (en) | 1991-05-10 | 1995-04-27 | Rhone-Poulenc Rorer International (Holdings) Inc. | Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
US5118677A (en) | 1991-05-20 | 1992-06-02 | American Home Products Corporation | Amide esters of rapamycin |
NZ243082A (en) | 1991-06-28 | 1995-02-24 | Ici Plc | 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof |
US5151413A (en) | 1991-11-06 | 1992-09-29 | American Home Products Corporation | Rapamycin acetals as immunosuppressant and antifungal agents |
GB9125660D0 (en) | 1991-12-03 | 1992-01-29 | Smithkline Beecham Plc | Novel compound |
AU661533B2 (en) | 1992-01-20 | 1995-07-27 | Astrazeneca Ab | Quinazoline derivatives |
US5521184A (en) | 1992-04-03 | 1996-05-28 | Ciba-Geigy Corporation | Pyrimidine derivatives and processes for the preparation thereof |
ZA935112B (en) | 1992-07-17 | 1994-02-08 | Smithkline Beecham Corp | Rapamycin derivatives |
ZA935111B (en) | 1992-07-17 | 1994-02-04 | Smithkline Beecham Corp | Rapamycin derivatives |
US5256790A (en) | 1992-08-13 | 1993-10-26 | American Home Products Corporation | 27-hydroxyrapamycin and derivatives thereof |
GB9221220D0 (en) | 1992-10-09 | 1992-11-25 | Sandoz Ag | Organic componds |
US5258389A (en) | 1992-11-09 | 1993-11-02 | Merck & Co., Inc. | O-aryl, O-alkyl, O-alkenyl and O-alkynylrapamycin derivatives |
WO1994011384A1 (en) | 1992-11-13 | 1994-05-26 | Immunex Corporation | Novel cytokine designated elk ligand |
US5455258A (en) | 1993-01-06 | 1995-10-03 | Ciba-Geigy Corporation | Arylsulfonamido-substituted hydroxamic acids |
US5629327A (en) | 1993-03-01 | 1997-05-13 | Childrens Hospital Medical Center Corp. | Methods and compositions for inhibition of angiogenesis |
US5516658A (en) | 1993-08-20 | 1996-05-14 | Immunex Corporation | DNA encoding cytokines that bind the cell surface receptor hek |
US5612340A (en) | 1993-10-01 | 1997-03-18 | Ciba-Geigy Corporation | Pyrimidineamine derivatives and processes for the preparation thereof |
US5656643A (en) | 1993-11-08 | 1997-08-12 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
JP4105761B2 (ja) | 1993-11-19 | 2008-06-25 | アボット・ラボラトリーズ | ラパミシン(マクロライド)の半合成類似体免疫調節剤 |
WO1995016691A1 (en) | 1993-12-17 | 1995-06-22 | Sandoz Ltd. | Rapamycin derivatives useful as immunosuppressants |
US5700823A (en) | 1994-01-07 | 1997-12-23 | Sugen, Inc. | Treatment of platelet derived growth factor related disorders such as cancers |
IL112248A0 (en) | 1994-01-25 | 1995-03-30 | Warner Lambert Co | Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them |
IL112249A (en) | 1994-01-25 | 2001-11-25 | Warner Lambert Co | Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds |
WO1995024190A2 (en) | 1994-03-07 | 1995-09-14 | Sugen, Inc. | Receptor tyrosine kinase inhibitors for inhibiting cell proliferative disorders and compositions thereof |
JPH09512167A (ja) | 1994-04-15 | 1997-12-09 | アムジエン・インコーポレーテツド | Hek5、hek7、hek8、hek11、新規なeph様受容体タンパク質チロシンキナーゼ |
DE59500788D1 (de) | 1994-05-03 | 1997-11-20 | Ciba Geigy Ag | Pyrrolopyrimidinderivate mit antiproliferativer Wirkung |
US6303769B1 (en) | 1994-07-08 | 2001-10-16 | Immunex Corporation | Lerk-5 dna |
US5919905A (en) | 1994-10-05 | 1999-07-06 | Immunex Corporation | Cytokine designated LERK-6 |
US6057124A (en) | 1995-01-27 | 2000-05-02 | Amgen Inc. | Nucleic acids encoding ligands for HEK4 receptors |
US5863949A (en) | 1995-03-08 | 1999-01-26 | Pfizer Inc | Arylsulfonylamino hydroxamic acid derivatives |
PT817775E (pt) | 1995-03-30 | 2002-01-30 | Pfizer | Derivados de quinazolina |
WO1996031510A1 (en) | 1995-04-03 | 1996-10-10 | Novartis Ag | Pyrazole derivatives and processes for the preparation thereof |
CA2218503C (en) | 1995-04-20 | 2001-07-24 | Pfizer Inc. | Arylsulfonyl hydroxamic acid derivatives |
GB9508538D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
US5747498A (en) | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
US5880141A (en) | 1995-06-07 | 1999-03-09 | Sugen, Inc. | Benzylidene-Z-indoline compounds for the treatment of disease |
US5650415A (en) | 1995-06-07 | 1997-07-22 | Sugen, Inc. | Quinoline compounds |
CA2219659C (en) | 1995-06-09 | 2008-03-18 | Novartis Ag | Rapamycin derivatives |
PT836605E (pt) | 1995-07-06 | 2002-07-31 | Novartis Ag | Pirrolopirimidinas e processos para a sua preparacao |
DE19534177A1 (de) | 1995-09-15 | 1997-03-20 | Merck Patent Gmbh | Cyclische Adhäsionsinhibitoren |
AR004010A1 (es) | 1995-10-11 | 1998-09-30 | Glaxo Group Ltd | Compuestos heterociclicos |
GB9523675D0 (en) | 1995-11-20 | 1996-01-24 | Celltech Therapeutics Ltd | Chemical compounds |
PT780386E (pt) | 1995-12-20 | 2003-02-28 | Hoffmann La Roche | Inibidores de metaloprotease de matriz |
WO1997027199A1 (en) | 1996-01-23 | 1997-07-31 | Novartis Ag | Pyrrolopyrimidines and processes for their preparation |
JP3406763B2 (ja) | 1996-01-30 | 2003-05-12 | 東レ・ダウコーニング・シリコーン株式会社 | シリコーンゴム組成物 |
GB9603097D0 (en) | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline compounds |
GB9603095D0 (en) | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline derivatives |
DE19608588A1 (de) | 1996-03-06 | 1997-09-11 | Thomae Gmbh Dr K | Pyrimido [5,4-d]pyrimidine, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
DE19629652A1 (de) | 1996-03-06 | 1998-01-29 | Thomae Gmbh Dr K | 4-Amino-pyrimidin-Derivate, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
DE59710417D1 (de) | 1996-03-15 | 2003-08-14 | Novartis Ag | N-7 HETEROCYCLYL-PYRROLO[ 2,3-d]PYRIMIDINE UND IHRE VERWENDUNG |
PL190489B1 (pl) | 1996-04-12 | 2005-12-30 | Warner Lambert Co | Nieodwracalne inhibitory kinaz tyrozyny, kompozycja farmaceutyczna je zawierająca i ich zastosowanie |
GB9607729D0 (en) | 1996-04-13 | 1996-06-19 | Zeneca Ltd | Quinazoline derivatives |
DE69734513T2 (de) | 1996-06-24 | 2006-07-27 | Pfizer Inc. | Phenylamino-substituierte tricyclische derivate zur behandlung hyperproliferativer krankheiten |
EP0818442A3 (en) | 1996-07-12 | 1998-12-30 | Pfizer Inc. | Cyclic sulphone derivatives as inhibitors of metalloproteinases and of the production of tumour necrosis factor |
EP0937082A2 (en) | 1996-07-12 | 1999-08-25 | Ariad Pharmaceuticals, Inc. | Materials and method for treating or preventing pathogenic fungal infection |
PT912559E (pt) | 1996-07-13 | 2003-03-31 | Glaxo Group Ltd | Compostos heterociclicos fundidos como inibidores de proteina tirosina quinase |
HRP970371A2 (en) | 1996-07-13 | 1998-08-31 | Kathryn Jane Smith | Heterocyclic compounds |
EP0912572B1 (en) | 1996-07-13 | 2003-01-15 | Glaxo Group Limited | Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors |
NZ333303A (en) | 1996-07-18 | 2000-06-23 | Lawrence Alan Reiter | Phosphinate based inhibitors of matrix metalloproteases |
US6111090A (en) | 1996-08-16 | 2000-08-29 | Schering Corporation | Mammalian cell surface antigens; related reagents |
AU4055697A (en) | 1996-08-16 | 1998-03-06 | Schering Corporation | Mammalian cell surface antigens; related reagents |
ATE384062T1 (de) | 1996-08-23 | 2008-02-15 | Novartis Pharma Gmbh | Substituierte pyrrolopyrimidine und verfahren zu ihrer herstellung |
BR9711223A (pt) | 1996-08-23 | 1999-08-17 | Pfizer | Derivados de cido arilsulfonilamino-hidrox mico |
WO1998014449A1 (en) | 1996-10-02 | 1998-04-09 | Novartis Ag | Fused pyrazole derivatives and processes for their preparation |
ID18494A (id) | 1996-10-02 | 1998-04-16 | Novartis Ag | Turunan pirazola leburan dan proses pembuatannya |
DE69732780T2 (de) | 1996-10-02 | 2006-04-06 | Novartis Ag | Pyrimiderivate und verfahren zu ihrer herstellung |
EP0837063A1 (en) | 1996-10-17 | 1998-04-22 | Pfizer Inc. | 4-Aminoquinazoline derivatives |
GB9621757D0 (en) | 1996-10-18 | 1996-12-11 | Ciba Geigy Ag | Phenyl-substituted bicyclic heterocyclyl derivatives and their use |
EP0950059B1 (en) | 1997-01-06 | 2004-08-04 | Pfizer Inc. | Cyclic sulfone derivatives |
IL131042A (en) | 1997-02-03 | 2004-07-25 | Pfizer Prod Inc | Derivatives of arylsulfonamic acid hydroxyamic acid and medicinal preparations containing them |
EP0964864B1 (en) | 1997-02-05 | 2008-04-09 | Warner-Lambert Company LLC | Pyrido 2,3-d pyrimidines and 4-aminopyrimidines as inhibitors of cellular proliferation |
EP0966438A1 (en) | 1997-02-07 | 1999-12-29 | Pfizer Inc. | N-hydroxy-beta-sulfonyl-propionamide derivatives and their use as inhibitors of matrix metalloproteinases |
HUP0000657A3 (en) | 1997-02-11 | 2000-10-30 | Pfizer | N-arylsulfonyl-piperidine, -morpholine hydroxamic acid derivatives and pharmaceutical compositions containing them |
CO4950519A1 (es) | 1997-02-13 | 2000-09-01 | Novartis Ag | Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion |
US6150395A (en) | 1997-05-30 | 2000-11-21 | The Regents Of The University Of California | Indole-3-carbinol (I3C) derivatives and methods |
AU8689298A (en) | 1997-08-05 | 1999-03-01 | Sugen, Inc. | Tricyclic quinoxaline derivatives as protein tyrosine kinase inhibitors |
ES2216293T3 (es) | 1997-08-08 | 2004-10-16 | Pfizer Products Inc. | Derivados de acido ariloxiarilsulfonilamino-hidroxamico. |
US6509173B1 (en) | 1997-10-21 | 2003-01-21 | Human Genome Sciences, Inc. | Human tumor necrosis factor receptor-like proteins TR11, TR11SV1, and TR11SV2 |
GB9725782D0 (en) | 1997-12-05 | 1998-02-04 | Pfizer Ltd | Therapeutic agents |
RS49779B (sr) | 1998-01-12 | 2008-06-05 | Glaxo Group Limited, | Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze |
GB9800575D0 (en) | 1998-01-12 | 1998-03-11 | Glaxo Group Ltd | Heterocyclic compounds |
GB9801690D0 (en) | 1998-01-27 | 1998-03-25 | Pfizer Ltd | Therapeutic agents |
AU2591599A (en) | 1998-02-09 | 1999-08-23 | Genentech Inc. | Novel tumor necrosis factor receptor homolog and nucleic acids encoding the same |
DE69940808D1 (de) | 1998-03-04 | 2009-06-10 | Bristol Myers Squibb Co | Heterocyclen substituierte imidazopyrazine als protein- tyrosin-kinase-inhibitoren |
PA8469401A1 (es) | 1998-04-10 | 2000-05-24 | Pfizer Prod Inc | Derivados biciclicos del acido hidroxamico |
PA8469501A1 (es) | 1998-04-10 | 2000-09-29 | Pfizer Prod Inc | Hidroxamidas del acido (4-arilsulfonilamino)-tetrahidropiran-4-carboxilico |
CO5031249A1 (es) | 1998-05-29 | 2001-04-27 | Sugen Inc | Pirrol substituido-2-indolinonas inhibidoras de proteinci-nasas |
UA60365C2 (uk) | 1998-06-04 | 2003-10-15 | Пфайзер Продактс Інк. | Похідні ізотіазолу, спосіб їх одержання, фармацевтична композиція та спосіб лікування гіперпроліферативного захворювання у ссавця |
JP2002520324A (ja) | 1998-07-10 | 2002-07-09 | メルク エンド カムパニー インコーポレーテッド | 新規な血管形成インヒビター |
CA2341409A1 (en) | 1998-08-31 | 2000-03-09 | Merck And Co., Inc. | Novel angiogenesis inhibitors |
EP1004578B1 (en) | 1998-11-05 | 2004-02-25 | Pfizer Products Inc. | 5-oxo-pyrrolidine-2-carboxylic acid hydroxamide derivatives |
EP1158985B1 (en) | 1999-01-13 | 2011-12-28 | Bayer HealthCare LLC | OMEGA-CARBOXY ARYL SUBSTITUTED DIPHENYL UREAS AS p38 KINASE INHIBITORS |
BR0009507A (pt) | 1999-03-30 | 2002-01-15 | Novartis Ag | Derivados de ftalazina para o tratamento de doenças inflamatórias |
GB9912961D0 (en) | 1999-06-03 | 1999-08-04 | Pfizer Ltd | Metalloprotease inhibitors |
US6521424B2 (en) | 1999-06-07 | 2003-02-18 | Immunex Corporation | Recombinant expression of Tek antagonists |
DK1187918T4 (da) | 1999-06-07 | 2009-02-23 | Immunex Corp | TEK-antagonister |
DE60036945T2 (de) | 1999-07-12 | 2008-08-21 | Genentech, Inc., South San Francisco | Stimulierung oder hemmung von angiogenese und herzvaskularisierung mit tumor nekrose faktor ligand/rezeptor homologen |
CA2383451A1 (en) | 1999-08-24 | 2001-03-01 | Ariad Gene Therapeutics, Inc. | 28-epirapalogs |
UA72946C2 (uk) | 1999-11-05 | 2005-05-16 | Астразенека Аб | Похідні хіназоліну як інгібітори васкулярного ендотеліального фактора росту (vegf) |
ES2367007T3 (es) | 1999-11-24 | 2011-10-27 | Sugen, Inc. | Derivados de indolinona ionizables y su uso como ligandos de ptk. |
US6515004B1 (en) | 1999-12-15 | 2003-02-04 | Bristol-Myers Squibb Company | N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]-carboxamide inhibitors of cyclin dependent kinases |
US6727225B2 (en) | 1999-12-20 | 2004-04-27 | Immunex Corporation | TWEAK receptor |
CA2400040A1 (en) | 2000-02-25 | 2001-08-30 | Immunex Corporation | Integrin antagonists |
US6630500B2 (en) | 2000-08-25 | 2003-10-07 | Cephalon, Inc. | Selected fused pyrrolocarbazoles |
MXPA03005696A (es) | 2000-12-21 | 2003-10-06 | Glaxo Group Ltd | Pirimidinaminas como moduladores de angiogenesis. |
US7105682B2 (en) | 2001-01-12 | 2006-09-12 | Amgen Inc. | Substituted amine derivatives and methods of use |
US6995162B2 (en) | 2001-01-12 | 2006-02-07 | Amgen Inc. | Substituted alkylamine derivatives and methods of use |
US7102009B2 (en) | 2001-01-12 | 2006-09-05 | Amgen Inc. | Substituted amine derivatives and methods of use |
US20020147198A1 (en) | 2001-01-12 | 2002-10-10 | Guoqing Chen | Substituted arylamine derivatives and methods of use |
US6878714B2 (en) | 2001-01-12 | 2005-04-12 | Amgen Inc. | Substituted alkylamine derivatives and methods of use |
US7307088B2 (en) | 2002-07-09 | 2007-12-11 | Amgen Inc. | Substituted anthranilic amide derivatives and methods of use |
TWI329112B (en) | 2002-07-19 | 2010-08-21 | Bristol Myers Squibb Co | Novel inhibitors of kinases |
CA2525717A1 (en) | 2003-05-23 | 2004-12-09 | Wyeth | Gitr ligand and gitr ligand-related molecules and antibodies and uses thereof |
AU2004255340B2 (en) | 2003-07-08 | 2008-05-01 | Novartis Ag | Use of rapamycin and rapamycin derivatives for the treatment of bone loss |
EP1660126A1 (en) | 2003-07-11 | 2006-05-31 | Schering Corporation | Agonists or antagonists of the clucocorticoid-induced tumour necrosis factor receptor (gitr) or its ligand for the treatment of immune disorders, infections and cancer |
WO2005016252A2 (en) | 2003-07-11 | 2005-02-24 | Ariad Gene Therapeutics, Inc. | Phosphorus-containing macrocycles |
AR045134A1 (es) | 2003-07-29 | 2005-10-19 | Smithkline Beecham Plc | Compuesto de 1h - imidazo [4,5-c] piridin-ilo, composicion farmaceutica que lo comprende, proceso para prepararla, su uso para preparar dicha composicion farmaceutica, combinacion farmaceutica, uso de la combinacion farmaceutica para la preparacion de un medicamento, procedimientos para preparar dic |
BRPI0413695A (pt) | 2003-08-22 | 2006-10-24 | Avanir Pharmaceuticals | derivados de naftiridina substituìda como inibidores do fator inibidor da migração de macrófagos e seu uso no tratamento de doenças humanas |
EP1692318A4 (en) | 2003-12-02 | 2008-04-02 | Genzyme Corp | COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TREATMENT OF LUNG CANCER |
GB0409799D0 (en) | 2004-04-30 | 2004-06-09 | Isis Innovation | Method of generating improved immune response |
WO2006083289A2 (en) | 2004-06-04 | 2006-08-10 | Duke University | Methods and compositions for enhancement of immunity by in vivo depletion of immunosuppressive cell activity |
PL1786785T3 (pl) | 2004-08-26 | 2010-08-31 | Pfizer | Enancjomerycznie czyste związki aminoheteroarylowe jako kinazy białkowe |
GT200500287A (es) | 2004-10-13 | 2006-04-17 | Analogos de 17-hidroxiwortmanina como inhibidores de pi3k | |
BRPI0516609A (pt) | 2004-10-18 | 2008-04-29 | Amgen Inc | composto ou sal, hidrato, ou estereoisÈmero farmaceuticamente aceitáveis do mesmo, composição farmacêutica, e, uso de um composto |
US7812135B2 (en) | 2005-03-25 | 2010-10-12 | Tolerrx, Inc. | GITR-binding antibodies |
NZ563193A (en) | 2005-05-09 | 2010-05-28 | Ono Pharmaceutical Co | Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics |
GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
KR20080040007A (ko) | 2005-09-20 | 2008-05-07 | 화이자 프로덕츠 인크. | 티로신 키나제 억제제를 이용한 치료의 투여형 및 방법 |
US7514566B2 (en) | 2006-01-18 | 2009-04-07 | Amgen, Inc. | Thiazole compounds and methods of use |
WO2007133822A1 (en) | 2006-01-19 | 2007-11-22 | Genzyme Corporation | Gitr antibodies for the treatment of cancer |
NZ578162A (en) | 2006-12-07 | 2011-12-22 | Genentech Inc | Phosphoinositide 3-kinase inhibitor compounds and methods of use |
US7919498B2 (en) | 2007-03-23 | 2011-04-05 | Amgen Inc. | Substituted pyrazolo[3,4-d]pyrimidines as PI3K inhibitors |
UA98955C2 (ru) | 2007-03-23 | 2012-07-10 | Амген Инк. | Гетероциклические соединения и их применение |
ES2446417T3 (es) | 2007-03-23 | 2014-03-07 | Amgen Inc. | Derivados de quinolina o quinoxalina sustituidos en 3 y su uso como inhibidores de fosfatidilinositol 3-cinasa (PI3K) |
US20110014117A1 (en) * | 2007-06-28 | 2011-01-20 | Schering Corporation | Anti-igf1r |
EP3124046B1 (en) | 2007-07-12 | 2019-12-25 | GITR, Inc. | Combination therapies employing gitr binding molecules |
EP2173728A2 (en) | 2007-07-17 | 2010-04-14 | Amgen Inc. | Heterocyclic modulators of pkb |
CA2693473A1 (en) | 2007-07-17 | 2009-01-22 | Amgen Inc. | Thiadiazole modulators of pkb |
ES2401557T3 (es) | 2007-08-02 | 2013-04-22 | Amgen, Inc | Moduladores de Pl3 cinasas y métodos de uso |
TWI471134B (zh) | 2007-09-12 | 2015-02-01 | Genentech Inc | 肌醇磷脂3-激酶抑制劑化合物及化療劑之組合及使用方法 |
EP2214675B1 (en) | 2007-10-25 | 2013-11-20 | Genentech, Inc. | Process for making thienopyrimidine compounds |
WO2009073869A1 (en) * | 2007-12-07 | 2009-06-11 | Bipar Sciences, Inc. | Treatment of cancer with combinations of topoisomerase inhibitors and parp inhibitors |
EP2231656A1 (en) | 2007-12-19 | 2010-09-29 | Amgen Inc. | Fused pyridine, pyrimidine and triazine compounds as cell cycle inhibitors |
WO2009085230A1 (en) | 2007-12-19 | 2009-07-09 | Amgen Inc. | Inhibitors of pi3 kinase |
CA2719538C (en) | 2008-04-07 | 2014-03-18 | Amgen Inc. | Gem-disubstituted and spirocyclic amino pyridines/pyrimidines as cell cycle inhibitors |
WO2009155121A2 (en) | 2008-05-30 | 2009-12-23 | Amgen Inc. | Inhibitors of pi3 kinase |
NZ590667A (en) | 2008-07-02 | 2013-01-25 | Emergent Product Dev Seattle | Tgf-b antagonist multi-target binding proteins |
CN102149820B (zh) | 2008-09-12 | 2014-07-23 | 国立大学法人三重大学 | 能够表达外源gitr配体的细胞 |
EP2387570A1 (en) | 2009-01-15 | 2011-11-23 | Amgen, Inc | Fluoroisoquinoline substituted thiazole compounds and methods of use |
MX2011008674A (es) | 2009-02-18 | 2011-11-04 | Amgen Inc | Compuestos de indol/bencimidazol como inhibidores de quinasa mtor. |
MX2011009796A (es) | 2009-03-20 | 2011-12-14 | Amgen Inc | Inhibidores de la cinasa pi3. |
UY32582A (es) | 2009-04-28 | 2010-11-30 | Amgen Inc | Inhibidores de fosfoinositida 3 cinasa y/u objetivo mamífero |
US20120190666A1 (en) | 2009-05-13 | 2012-07-26 | Amgen Inc. | Heteroaryl Compounds as PIKK Inhibitors |
EP2445900B1 (en) | 2009-06-25 | 2016-03-02 | Amgen, Inc | Polycyclic derivatives of pyridine and their use in the treatment of (inter alia) rheumatoid arthritis and similar diseases |
EP2445898A2 (en) | 2009-06-25 | 2012-05-02 | Amgen, Inc | 4h-pyrido[1,2-a]pyrimidin-4-one derivatives as pi3k inhibitors |
JP2012531436A (ja) | 2009-06-25 | 2012-12-10 | アムジエン・インコーポレーテツド | 複素環式化合物およびそれらのpi3k活性阻害剤としての使用 |
CA2765823A1 (en) | 2009-06-25 | 2010-12-29 | Amgen Inc. | Tricyclic heterocyclic compounds as mediators of p13k activity |
EP2266984A1 (en) | 2009-06-26 | 2010-12-29 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Pyrido[2,3-d]pyrimidines as Wnt antagonists for treatment of cancer and arthritis |
RU2595409C2 (ru) | 2009-09-03 | 2016-08-27 | Мерк Шарп И Доум Корп., | Анти-gitr-антитела |
GB0919054D0 (en) | 2009-10-30 | 2009-12-16 | Isis Innovation | Treatment of obesity |
JP5856073B2 (ja) | 2009-12-29 | 2016-02-09 | エマージェント プロダクト デベロップメント シアトル, エルエルシー | Ron結合構築体およびその使用方法 |
US9133164B2 (en) | 2011-04-13 | 2015-09-15 | Innov88 Llc | MIF inhibitors and their uses |
WO2013039954A1 (en) | 2011-09-14 | 2013-03-21 | Sanofi | Anti-gitr antibodies |
EP2836482B1 (en) | 2012-04-10 | 2019-12-25 | The Regents of The University of California | Compositions and methods for treating cancer |
US9745319B2 (en) | 2013-03-15 | 2017-08-29 | Araxes Pharma Llc | Irreversible covalent inhibitors of the GTPase K-Ras G12C |
AU2014239542A1 (en) | 2013-03-15 | 2015-10-01 | Araxes Pharma Llc | Covalent inhibitors of KRas G12C |
US9227978B2 (en) | 2013-03-15 | 2016-01-05 | Araxes Pharma Llc | Covalent inhibitors of Kras G12C |
GB201312059D0 (en) | 2013-07-05 | 2013-08-21 | Univ Leuven Kath | Novel GAK modulators |
JO3805B1 (ar) | 2013-10-10 | 2021-01-31 | Araxes Pharma Llc | مثبطات كراس جي12سي |
EP3055290B1 (en) | 2013-10-10 | 2019-10-02 | Araxes Pharma LLC | Inhibitors of kras g12c |
GB201320729D0 (en) | 2013-11-25 | 2014-01-08 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
EP3164121A4 (en) * | 2014-07-01 | 2018-06-13 | Vicus Therapeutics, LLC | Combination drug therapies for cancer and methods of making and using them |
JO3556B1 (ar) | 2014-09-18 | 2020-07-05 | Araxes Pharma Llc | علاجات مدمجة لمعالجة السرطان |
US10011600B2 (en) | 2014-09-25 | 2018-07-03 | Araxes Pharma Llc | Methods and compositions for inhibition of Ras |
ES2826443T3 (es) | 2014-09-25 | 2021-05-18 | Araxes Pharma Llc | Inhibidores de proteínas mutantes KRAS G12C |
WO2016049565A1 (en) | 2014-09-25 | 2016-03-31 | Araxes Pharma Llc | Compositions and methods for inhibition of ras |
KR20180005178A (ko) | 2015-04-10 | 2018-01-15 | 아락세스 파마 엘엘씨 | 치환된 퀴나졸린 화합물 및 이의 사용방법 |
JP6789239B2 (ja) | 2015-04-15 | 2020-11-25 | アラクセス ファーマ エルエルシー | Krasの縮合三環系インヒビターおよびその使用の方法 |
EP3325447A1 (en) | 2015-07-22 | 2018-05-30 | Araxes Pharma LLC | Substituted quinazoline compounds and their use as inhibitors of g12c mutant kras, hras and/or nras proteins |
EP3356354A1 (en) | 2015-09-28 | 2018-08-08 | Araxes Pharma LLC | Inhibitors of kras g12c mutant proteins |
EP3356351A1 (en) | 2015-09-28 | 2018-08-08 | Araxes Pharma LLC | Inhibitors of kras g12c mutant proteins |
US10858343B2 (en) | 2015-09-28 | 2020-12-08 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
EP3356349A1 (en) | 2015-09-28 | 2018-08-08 | Araxes Pharma LLC | Inhibitors of kras g12c mutant proteins |
EP3356339A1 (en) | 2015-09-28 | 2018-08-08 | Araxes Pharma LLC | Inhibitors of kras g12c mutant proteins |
US10882847B2 (en) | 2015-09-28 | 2021-01-05 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
US10875842B2 (en) | 2015-09-28 | 2020-12-29 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
EA038635B9 (ru) | 2015-11-16 | 2021-10-26 | Араксис Фарма Ллк | 2-замещенные соединения хиназолина, содержащие замещенную гетероциклическую группу, и способы их применения |
WO2017100546A1 (en) | 2015-12-09 | 2017-06-15 | Araxes Pharma Llc | Methods for preparation of quinazoline derivatives |
US10822312B2 (en) | 2016-03-30 | 2020-11-03 | Araxes Pharma Llc | Substituted quinazoline compounds and methods of use |
WO2017201161A1 (en) | 2016-05-18 | 2017-11-23 | Mirati Therapeutics, Inc. | Kras g12c inhibitors |
US10646488B2 (en) | 2016-07-13 | 2020-05-12 | Araxes Pharma Llc | Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof |
JP2019529484A (ja) | 2016-09-29 | 2019-10-17 | アラクセス ファーマ エルエルシー | Kras g12c変異体タンパク質の阻害剤 |
CN110312711A (zh) | 2016-10-07 | 2019-10-08 | 亚瑞克西斯制药公司 | 作为ras抑制剂的杂环化合物及其使用方法 |
RS62456B1 (sr) | 2016-12-22 | 2021-11-30 | Amgen Inc | Derivati benzizotiazola, izotiazolo[3,4-b]piridina, hinazolina, ftalazina, pirido[2,3-d]piridazina i pirido[2,3-d]pirimidina kao kras g12c inhibitori za tretman raka pluća, pankreasa ili debelog creva |
CN110382483A (zh) | 2017-01-26 | 2019-10-25 | 亚瑞克西斯制药公司 | 稠合的n-杂环化合物及其使用方法 |
JOP20190272A1 (ar) | 2017-05-22 | 2019-11-21 | Amgen Inc | مثبطات kras g12c وطرق لاستخدامها |
CN110831933A (zh) | 2017-05-25 | 2020-02-21 | 亚瑞克西斯制药公司 | 喹唑啉衍生物作为突变kras、hras或nras的调节剂 |
CA3075046A1 (en) | 2017-09-08 | 2019-03-14 | Amgen Inc. | Inhibitors of kras g12c and methods of using the same |
MA52496A (fr) | 2018-05-04 | 2021-03-10 | Amgen Inc | Inhibiteurs de kras g12c et leurs procédés d'utilisation |
MA52501A (fr) | 2018-05-04 | 2021-03-10 | Amgen Inc | Inhibiteurs de kras g12c et leurs procédés d'utilisation |
WO2019217691A1 (en) | 2018-05-10 | 2019-11-14 | Amgen Inc. | Kras g12c inhibitors for the treatment of cancer |
JP7360396B2 (ja) | 2018-06-01 | 2023-10-12 | アムジエン・インコーポレーテツド | Kras g12c阻害剤及び同一物の使用方法 |
JP7357644B2 (ja) | 2018-06-11 | 2023-10-06 | アムジエン・インコーポレーテツド | がんを処置するためのkras g12c阻害剤 |
WO2020050890A2 (en) | 2018-06-12 | 2020-03-12 | Amgen Inc. | Kras g12c inhibitors and methods of using the same |
JP2021528404A (ja) | 2018-06-21 | 2021-10-21 | ヤンセン ファーマシューティカ エヌ.ベー. | Oga阻害剤化合物 |
JP2021527687A (ja) | 2018-06-21 | 2021-10-14 | ヤンセン ファーマシューティカ エヌ.ベー. | Oga阻害剤化合物 |
JP7516029B2 (ja) | 2018-11-16 | 2024-07-16 | アムジエン・インコーポレーテツド | Kras g12c阻害剤化合物の重要な中間体の改良合成法 |
JP7377679B2 (ja) | 2018-11-19 | 2023-11-10 | アムジエン・インコーポレーテツド | がん治療のためのkrasg12c阻害剤及び1種以上の薬学的に活性な追加の薬剤を含む併用療法 |
WO2020106640A1 (en) | 2018-11-19 | 2020-05-28 | Amgen Inc. | Kras g12c inhibitors and methods of using the same |
EP3738593A1 (en) | 2019-05-14 | 2020-11-18 | Amgen, Inc | Dosing of kras inhibitor for treatment of cancers |
JP2022532790A (ja) | 2019-05-21 | 2022-07-19 | アムジエン・インコーポレーテツド | 固体形態 |
MX2021014126A (es) | 2019-05-21 | 2022-01-04 | Amgen Inc | Formas en estado solido. |
MX2022004656A (es) | 2019-10-24 | 2022-05-25 | Amgen Inc | Derivados de piridopirimidina utiles como inhibidores de kras g12c y kras g12d en el tratamiento del cancer. |
US20230192682A1 (en) | 2019-11-14 | 2023-06-22 | Amgen Inc. | Improved synthesis of kras g12c inhibitor compound |
BR112022009390A2 (pt) | 2019-11-14 | 2022-08-09 | Amgen Inc | Síntese melhorada de composto inibidor de kras g12c |
US20230028414A1 (en) | 2019-12-16 | 2023-01-26 | Amgen Inc. | Dosing regimen of kras g12c inhibitor |
US20230183235A1 (en) | 2020-05-20 | 2023-06-15 | Teva Pharmaceuticals International Gmbh | Solid state forms of amg-510 and process for preparation thereof |
-
2019
- 2019-11-08 EP EP19208193.3A patent/EP3738593A1/en active Pending
-
2020
- 2020-05-13 BR BR112021022812A patent/BR112021022812A2/pt unknown
- 2020-05-13 SG SG11202112432PA patent/SG11202112432PA/en unknown
- 2020-05-13 EP EP20728881.2A patent/EP3968998A1/en active Pending
- 2020-05-13 CA CA3139519A patent/CA3139519A1/en active Pending
- 2020-05-13 US US15/930,606 patent/US11426404B2/en active Active
- 2020-05-13 CN CN202080035771.8A patent/CN113840606B/zh active Active
- 2020-05-13 MA MA055959A patent/MA55959A/fr unknown
- 2020-05-13 JP JP2021500906A patent/JP6963146B1/ja active Active
- 2020-05-13 WO PCT/US2020/032686 patent/WO2020232130A1/en unknown
- 2020-05-13 AU AU2020275845A patent/AU2020275845A1/en active Pending
- 2020-05-13 MX MX2021013788A patent/MX2021013788A/es unknown
- 2020-05-14 TW TW109116077A patent/TWI824148B/zh active
- 2020-05-14 TW TW112133383A patent/TWI826344B/zh active
-
2021
- 2021-10-13 JP JP2021168089A patent/JP7265600B2/ja active Active
- 2021-11-04 IL IL287838A patent/IL287838A/en unknown
-
2022
- 2022-07-22 US US17/871,178 patent/US20220378787A1/en not_active Abandoned
-
2023
- 2023-04-13 JP JP2023065418A patent/JP7300076B1/ja active Active
- 2023-06-15 JP JP2023098289A patent/JP2023116708A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
MA55959A (fr) | 2022-03-23 |
JP7265600B2 (ja) | 2023-04-26 |
SG11202112432PA (en) | 2021-12-30 |
TWI826344B (zh) | 2023-12-11 |
CN113840606A (zh) | 2021-12-24 |
EP3968998A1 (en) | 2022-03-23 |
EP3738593A1 (en) | 2020-11-18 |
CA3139519A1 (en) | 2020-11-19 |
JP2022009090A (ja) | 2022-01-14 |
MX2021013788A (es) | 2022-05-18 |
JP7300076B1 (ja) | 2023-06-28 |
US20220378787A1 (en) | 2022-12-01 |
JP2021534080A (ja) | 2021-12-09 |
WO2020232130A1 (en) | 2020-11-19 |
CN113840606B (zh) | 2024-08-30 |
BR112021022812A2 (pt) | 2021-12-28 |
US20200360374A1 (en) | 2020-11-19 |
AU2020275845A1 (en) | 2021-12-02 |
JP2023095870A (ja) | 2023-07-06 |
IL287838A (en) | 2022-01-01 |
TW202348233A (zh) | 2023-12-16 |
JP2023116708A (ja) | 2023-08-22 |
TW202108142A (zh) | 2021-03-01 |
US11426404B2 (en) | 2022-08-30 |
TWI824148B (zh) | 2023-12-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6963146B1 (ja) | 癌を治療するためのkras阻害剤の投与 | |
US20230248729A1 (en) | Dosing regimen of kras g12c inhibitor | |
US20240139193A1 (en) | Combination therapy of kras inhibitor and shp2 inhibitor for treatment of cancers | |
US20230146638A1 (en) | Treatment of EGFR-Driven Cancer with Fewer Side Effects | |
JP7286755B2 (ja) | (s)-5-アミノ-3-(4-((5-フルオロ-2-メトキシベンズアミド)メチル)フェニル)-1-(1,1,1-トリフルオロプロパン-2-イル)-1h-ピラゾール-4-カルボキサミドの噴霧乾燥分散体および製剤 | |
JP2021107465A (ja) | N−(シアノメチル)−4−(2−(4−モルホリノフェニルアミノ)ピリミジン−4−イル)ベンズアミド塩酸塩 | |
US11395821B2 (en) | Treatment of EGFR-driven cancer with fewer side effects | |
KR20140043314A (ko) | 이중 오로라 키나제/mek 억제제를 사용한 항암 치료법 | |
US20240166668A1 (en) | Compounds and uses thereof | |
US20120308562A1 (en) | Methods of treating mesothelioma with a pi3k inhibitor compound | |
JP2024526145A (ja) | Kras g12c阻害剤を含む組合せ医薬及び癌の治療のためのその使用 | |
AU2022243600A1 (en) | Alk-5 inhibitors and uses thereof | |
KR20220008870A (ko) | 노치-활성화 유방암을 치료하기 위한 비스플루오로알킬-1,4-벤조디아제피논 화합물 | |
EA047200B1 (ru) | Введение доз ингибитора kras для лечения форм рака | |
US20230090742A1 (en) | Aminopyrimidinylaminobenzonitrile derivatives as nek2 inhibitors | |
AU2021359826A1 (en) | Dosing regimens for cyclin‑dependent kinase 7 (cdk7) inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210413 Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210112 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20210112 |
|
A871 | Explanation of circumstances concerning accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A871 Effective date: 20210413 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20211012 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20211014 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6963146 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R153 | Grant of patent term extension |
Free format text: JAPANESE INTERMEDIATE CODE: R153 |